Media coverage about Opexa Therapeutics (NASDAQ:OPXA) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Opexa Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.5694574706462 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Separately, Zacks Investment Research upgraded shares of Opexa Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 24th.

Opexa Therapeutics (NASDAQ OPXA) opened at 0.915 on Friday. Opexa Therapeutics has a 52-week low of $0.50 and a 52-week high of $4.93. The company’s market cap is $7.01 million. The stock has a 50 day moving average of $0.71 and a 200-day moving average of $0.80.

Opexa Therapeutics (NASDAQ:OPXA) last released its quarterly earnings results on Friday, May 12th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter. Opexa Therapeutics had a negative return on equity of 150.46% and a negative net margin of 274.79%. On average, analysts forecast that Opexa Therapeutics will post ($0.47) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Opexa Therapeutics (NASDAQ:OPXA) Share Price” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at

Opexa Therapeutics Company Profile

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.

Insider Buying and Selling by Quarter for Opexa Therapeutics (NASDAQ:OPXA)

Receive News & Stock Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related stocks with our FREE daily email newsletter.